STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu dopisy, práce podpořená grantem
PubMed
33247178
PubMed Central
PMC8102183
DOI
10.1038/s41375-020-01093-1
PII: 10.1038/s41375-020-01093-1
Knihovny.cz E-zdroje
- MeSH
- anaplastický velkobuněčný lymfom genetika patologie MeSH
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mutace genetika MeSH
- nádorový supresorový protein p53 genetika MeSH
- předškolní dítě MeSH
- prognóza MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- transkripční faktor STAT3 genetika MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- Názvy látek
- nádorový supresorový protein p53 MeSH
- STAT3 protein, human MeSH Prohlížeč
- TP53 protein, human MeSH Prohlížeč
- transkripční faktor STAT3 MeSH
Department of Medicine and Surgery University of Milano Bicocca Monza Italy
Department of Pathology Medical University of Vienna Vienna Austria
Zobrazit více v PubMed
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504. doi: 10.1182/blood-2008-01-134270. PubMed DOI
Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol. 2019. http://link.springer.com/10.1007/s00277-019-03694-y. PubMed DOI
Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;2:17–25. https://pubmed.ncbi.nlm.nih.gov/25869285/. PubMed
Brugières L, Deley MC Le, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, et al. CD30+ anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591–8. PubMed
Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K, et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2013;27:416–22. doi: 10.1038/leu.2012.205. PubMed DOI
Morel A, Brière J, Lamant L, Loschi M, Haioun C, Delarue R, et al. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: a LYSA/SFGM-TC study. Eur J Cancer. 2017;83:146–53. doi: 10.1016/j.ejca.2017.06.026. PubMed DOI
Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, et al. Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: Report of the ALCL99 randomised trial. Pediatr Blood Cancer. 2011;56:1071–7. doi: 10.1002/pbc.22940. PubMed DOI
Prokoph N, Larose H, Lim MS, Burke GAA, Turner SD. Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond. Cancers. 2018;10:1–18. doi: 10.3390/cancers10040099. PubMed DOI PMC
Crescenzo R, Abate F, Lasorsa E, Tabbo’ F, Gaudiano M, Chiesa N, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27:516–32. doi: 10.1016/j.ccell.2015.03.006. PubMed DOI PMC
Larose H, Prokoph N, Matthews JD, Schlederer M, Högler S, Alsulami AF, et al. Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. 2020. http://www.haematologica.org/lookup/doi/10.3324/haematol.2019.238766. PubMed DOI PMC
Song TL, Nairismägi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood. 2018;132:1146–58. doi: 10.1182/blood-2018-01-829424. PubMed DOI PMC
Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbò F, et al. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood. 2013;122:2683–93. doi: 10.1182/blood-2013-04-497933. PubMed DOI
Andersson EI, Brück O, Braun T, Mannisto S, Saikko L, Lagström S, et al. STAT3 mutation is associated with STAT3 activation in CD30+ ALK− ALCL. Cancers. 2020;12:702. doi: 10.3390/cancers12030702. PubMed DOI PMC
Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, et al. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL. Blood. 2020;135:360–70. PubMed PMC
Shen J, Li S, Medeiros LJ, Lin P, Wang SA, Tang G, et al. PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. Mod Pathol. 2020;33:324–33. doi: 10.1038/s41379-019-0336-3. PubMed DOI
Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib
ClinicalTrials.gov
NCT03199066
